Gil M. Labrucherie, SVP, COO & CFO at NEKTAR THERAPEUTICS (NKTR), sold 248,067 shares at $19.97 ($4.9M) on 2021-02-02, disclosed to the SEC on 2021-02-04.
Seasonal sale ($4.9M) by SVP, COO & CFO — this insider has traded NKTR in February in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.97 | 41,135 | $821K | 16.6% |
| 2 | $19.97 | 41,135 | $821K | 16.6% |
| 3 | $20.96 | 6,932 | $145K | 2.9% |
| 4 | $20.96 | 6,932 | $145K | 2.9% |
| 5 | $21.66 | 1,933 | $42K | 0.8% |
| 6 | $19.61 | 50,000 |
| $981K |
| 19.9% |
| 7 | $19.81 | 50,000 | $990K | 20.1% |
| 8 | $19.81 | 50,000 | $991K | 20.1% |
| Total | $19.90 avg | 248,067 | $4.9M | 100% |
| Filing → |
| NKTR | SELL | 2022-05-17 | $138K | — | Filing → |
| RZLT | BUY | 2022-05-09 | $400K | — | Filing → |
| NKTR | SELL | 2022-02-18 | $166K | — | Filing → |